Some Thoughts on Terns Pharmaceuticals

By Chris Stiles • Wednesday, November 29 17:20 • Permanent Link

Shares of Terns Pharmaceuticals have moved 1.7% today, and are now trading at a price of $4.16. In contrast, the S&P 500 index saw a -0.0% change. Today's trading volume is 240,459 compared to the stock's average volume of 457,957.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. Based in Foster City, United States the company has 46 full time employees and a market cap of $257,065,104.

The company is now trading -70.89% away from its average analyst target price of $14.29 per share. The 7 analysts following the stock have set target prices ranging from $8.0 to $19.0, and on average give Terns Pharmaceuticals a rating of buy.

Date Reported	Total Revenue ($ k)	Net Profit ($ k)	Net Margins (%)
2023	nan	-85,013	nan
2022	nan	-60,345	nan
2021	1,000	-50,158	-5015.8
2020	nan	-518	nan

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.